{"schema_version":"1","generated_at":"2026-11-08T07:48:10.724Z","data_as_of":null,"url":"https://www.findmykol.com/kol/mahesh-swaminathan","json_url":"https://www.findmykol.com/kol/mahesh-swaminathan/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"mahesh-swaminathan","name":"Mahesh Swaminathan","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"The University of Texas MD Anderson Cancer Center","institution_url":"https://www.findmykol.com/institution/the-university-of-texas-md-anderson-cancer-center","city":"Houston","state":"TX","region":{"label":"South Central","url":"https://www.findmykol.com/region/south-central"}},"identifiers":{"npi":"1851798284","orcid":"0000-0001-5959-397X","openalex":"A5050673025"},"summary":"Mahesh Swaminathan is an Oncology physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 131 publications with 674 citations (h-index 13); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":131,"cited_by_count":674,"h_index":13,"latest_activity_year":2026,"emerging":true,"source":"works"},"trials":{"count":1,"shown":2,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT07566364","title":"Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD","phase":"PHASE2","status":"RECRUITING","role":"Overall official","sponsor":"M.D. Anderson Cancer Center","source_url":"https://clinicaltrials.gov/study/NCT07566364","trial_url":"https://www.findmykol.com/trial/NCT07566364"},{"nct":"NCT06619522","title":"A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis","phase":"PHASE2","status":"WITHDRAWN","role":"Overall official","sponsor":"M.D. Anderson Cancer Center","source_url":"https://clinicaltrials.gov/study/NCT06619522","trial_url":"https://www.findmykol.com/trial/NCT06619522"}],"source":"trials"},"payments":{"company_count":17,"program_years":{"first":2021,"last":null},"rows_total":25,"shown":3,"withheld":22,"rows":[{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":8796.12,"payment_count":6,"source_url":"https://openpaymentsdata.cms.gov/search?query=1851798284"},{"payer":"Daiichi Sankyo Inc.","program_year":2025,"amount_usd":650,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1851798284"},{"payer":"Genentech, Inc.","program_year":2025,"amount_usd":137.27,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1851798284"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1851798284","source":"payments"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes","year":2026,"journal":"Blood Cancer Journal","source_url":"https://doi.org/10.1038/s41408-026-01479-x","status":"verified"},{"title":"NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy","year":2026,"journal":"Blood Advances","source_url":"https://doi.org/10.1182/bloodadvances.2026020243","status":"verified"},{"title":"Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia","year":2025,"journal":"Leukemia","source_url":"https://doi.org/10.1038/s41375-025-02531-8","status":"verified"},{"title":"Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients","year":2025,"journal":"Blood Cancer Journal","source_url":"https://doi.org/10.1038/s41408-025-01269-x","status":"verified"},{"title":"Clinico‐Genomic Interrogation of Secondary‐Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies","year":2025,"journal":"American Journal of Hematology","source_url":"https://doi.org/10.1002/ajh.27628","status":"verified"}],"source":"works"},"contact":{"address_1":"1515 HOLCOMBE BLVD","city":"Houston","state":"TX","zip":"770304000","phone":"713-792-6161","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1851798284","source":"identity"},"similar":[{"name":"Hagop Kantarjian","slug":"hagop-kantarjian","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/hagop-kantarjian","json_url":"https://www.findmykol.com/kol/hagop-kantarjian/profile.json"},{"name":"Gabriel Hortobagyi","slug":"gabriel-hortobagyi","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/gabriel-hortobagyi","json_url":"https://www.findmykol.com/kol/gabriel-hortobagyi/profile.json"},{"name":"Jaffer Ajani","slug":"jaffer-ajani","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/jaffer-ajani","json_url":"https://www.findmykol.com/kol/jaffer-ajani/profile.json"},{"name":"Funda Meric-Bernstam","slug":"funda-meric-bernstam","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Surgery","url":"https://www.findmykol.com/kol/funda-meric-bernstam","json_url":"https://www.findmykol.com/kol/funda-meric-bernstam/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":22,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2022-08-08","provider_certified":"2022-08-08","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}